Craniospinal irradiation using helical tomotherapy for central nervous system tumors

Area of Science:

• Radiation Oncology
• Neuro-oncology
• Medical Physics

Background:

• Craniospinal irradiation is a critical treatment for various primary brain tumors.
• Helical tomotherapy (HT) offers advanced radiation delivery capabilities.
• Evaluating HT-CSI's efficacy and toxicity is essential for optimizing patient outcomes.

Purpose of the Study:

• To assess early and late toxicity, survival rates, and local control in patients with primary brain tumors treated with HT-CSI.
• To compare the outcomes of HT-CSI with conventional radiotherapy techniques.
• To identify factors influencing survival in patients undergoing HT-CSI.

Main Methods:

• Retrospective analysis of 45 patients with central nervous system malignancies treated with HT-CSI between 2006 and 2014.
• Detailed documentation of hematological and acute toxicities (leukopenia, anemia, thrombocytopenia, nausea, vomiting, fatigue, alopecia, neurotoxicity).
• Evaluation of local control, survival rates (3- and 5-year), and secondary cancer development.

Main Results:

• The most common diagnoses were medulloblastoma (20), ependymoma (10), and intracranial germinoma (7).
• Acute toxicities were generally manageable, with no Grade 3 or higher late toxicity observed.
• Overall 3- and 5-year survival rates were 80% and 70%, respectively, with specific rates for different tumor types.
• Local relapse occurred in 10 patients (24.4%).

Conclusions:

• HT-CSI is a safe and effective treatment for primary brain tumors, yielding survival rates comparable to existing literature.
• HT-CSI provides dosimetric advantages, including precise target coverage and reduced dose to organs at risk.
• The technique facilitates quicker recovery from acute toxicities and potentially improves long-term outcomes.